IMMUNOVIA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.804 SEK | -0.33% |
|
-11.13% | +1.81% |
| Apr. 29 | Transcript : Immunovia AB, Q1 2024 Earnings Call, Apr 29, 2024 | |
| Apr. 29 | Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina | CI |
Presenter SpeechPatrik Dahlen (Executives)Good afternoon, and good morning, everyone. Welcome ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunoviaâs test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.
Calendar
2024-06-04
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| +1.81% | 7.56M | |
| -40.46% | 2.93B | |
| +22.80% | 1.95B | |
| +7.25% | 1.79B | |
| +26.48% | 1.25B | |
| -6.82% | 1.07B | |
| -17.45% | 948M | |
| -1.10% | 770M | |
| -22.68% | 648M | |
| +7.08% | 501M |
- Stock Market
- Equities
- IMMNOV Stock
- News Immunovia AB
- Transcript : Immunovia AB - Shareholder/Analyst Call